electroCore (ECOR) vs Hyperfine (HYPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
electroCore (ECOR) has outperformed Hyperfine (HYPR) over the past year, losing 6.2% versus a loss of 48.0%. Over five years, ECOR leads with a -61.2% price change compared with -94.5% for HYPR. Hyperfine is the larger company by market cap ($58.0 million vs $40.8 million), about 1.4 times the size, while electroCore is growing revenue faster (+27.2% vs +5.2%).
electroCore converts more of its revenue into profit, with a net margin of -43.6% versus -262.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ECOR | HYPR |
|---|---|---|
| Share price | $4.42 | $0.5465 |
| Market cap | $40.78M | $57.96M |
| 1-day change | -8.87% | +4.27% |
| YTD return | -1.45% | -44.18% |
| 1-year return | -6.16% | -47.95% |
| 5-year return | -61.23% | -94.45% |
| EPS (TTM) | $-1.36 | $-0.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $32.03M | $13.56M |
| Revenue growth (YoY) | +27.20% | +5.22% |
| Net income (latest FY) | $-13.97M | $-35.57M |
| Gross margin | 86.75% | 49.79% |
| Operating margin | -41.06% | -273.43% |
| Net margin | -43.60% | -262.29% |
| 52-week high | $12.70 | $1.94 |
| 52-week low | $3.90 | $0.488 |
| Distance from 52-week high | -65.20% | -71.76% |
| Analyst consensus | none | none |
| Avg. price target upside | +333.71% | +271.45% |
| Average volume | 120.32K | 760.76K |
| Shares outstanding | 9.23M | 90.99M |
| Employees | 83 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ECOR has outperformed HYPR by 41.8 percentage points over the past year.
- electroCore is more profitable, keeping -43.6 cents of every revenue dollar as net income versus -262.3 cents for Hyperfine.
- electroCore grew revenue faster in its latest fiscal year (+27.20% vs +5.22%).
About electroCore
ECOR stock →electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 83 employees
About Hyperfine
HYPR stock →Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 102 employees
ECOR vs HYPR FAQ
Which is bigger, electroCore or Hyperfine?
Hyperfine (HYPR) is larger, with a market capitalization of $57.96M compared with $40.78M for electroCore (ECOR).
Which stock has performed better over the past year, ECOR or HYPR?
ECOR returned -6.16% over the past 12 months, compared with -47.95% for HYPR (price return, excluding dividends). Past performance does not predict future results.
Are electroCore and Hyperfine in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.